Journal: Materials Today Bio

Article Title: Copper-based nanozymes synergistically enhance Cuproptosis for psoriasis treatment

doi: 10.1016/j.mtbio.2026.102855

Figure Lengend Snippet: Studies on cuproptosis mediated by Cu-NZs in vitro. (a) Schematic illustration of the cuproptosis pathway. (b–d) Relative mRNA expression levels of cuproptosis-related genes (DLAT, FDX1, LIAS) in HaCaT cells treated with Cu-NZs (7.5 and 15 μg/mL) for 24 h. (e–g) Western blot analysis of cuproptosis-related proteins (DLAT, FDX1, LIAS) in HaCaT cells treated with Cu-NZs (7.5 and 15 μg/mL) for 24 h. (h,i) Confocal microscopy images showing expression and subcellular localization changes of cuproptosis-related proteins (DLAT, LIAS and FDX1) in HaCaT cells treated with Cu-NZs (7.5 and 15 μg/mL) for 24 h (representative images shown). All data are presented as mean ± SD (n = 3). Statistical comparisons were performed using one-way ANOVA followed by Tukey's post hoc test. Significance levels are indicated as follows: ∗∗p < 0.01, ∗∗∗p < 0.001, and ∗∗∗∗p < 0.0001.

Article Snippet: Post-transfer, membranes were blocked with 5 % skim milk (1 h, RT), probed overnight at 4 °C with primary antibodies: DLAT (Proteintech #13426-1-AP, 1:4000), FDX1 (#12592-1-AP, 1:5000), LIAS (#11577-1-AP, 1:2000), GAPDH (#60004-1-Ig, 1:10000), α-Tubulin (#11224-1-AP, 1:5000), washed with TBST, incubated with HRP-conjugated secondaries, and detected using ECL on an Odyssey® Fc system.

Techniques: In Vitro, Expressing, Western Blot, Confocal Microscopy

Journal: Materials Today Bio

Article Title: Copper-based nanozymes synergistically enhance Cuproptosis for psoriasis treatment

doi: 10.1016/j.mtbio.2026.102855

Figure Lengend Snippet: In vivo alleviation of psoriatic-like lesions by Cu-NZs in C57 mice. (a) Experimental schedule of the therapeutic regimen in IMQ-induced psoriatic mouse models. (b–e) Psoriasis Area and Severity Index (PASI) scores assessing erythema, scaling, and skin thickness. (f) Macroscopic skin appearance and corresponding H&E-stained skin sections. (g) Epidermal thickness measurements from H&E-stained sections. (h–j) mRNA expression levels of inflammatory cytokines in skin tissues. (k) Expression of cuproptosis-related proteins (DLAT, LIAS, FDX1) in mouse skin as detected by IHC. (l–o) Liver and kidney function markers: alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum creatinine (SCr), and blood urea nitrogen (BUN). All data are presented as mean ± SD (n = 5 per group). For comparisons between two groups, an unpaired t -test was used. For comparisons involving three or more groups, one-way ANOVA followed by Tukey's post hoc test was performed. Significance levels are indicated as follows: ns, not significant; ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001.

Article Snippet: Post-transfer, membranes were blocked with 5 % skim milk (1 h, RT), probed overnight at 4 °C with primary antibodies: DLAT (Proteintech #13426-1-AP, 1:4000), FDX1 (#12592-1-AP, 1:5000), LIAS (#11577-1-AP, 1:2000), GAPDH (#60004-1-Ig, 1:10000), α-Tubulin (#11224-1-AP, 1:5000), washed with TBST, incubated with HRP-conjugated secondaries, and detected using ECL on an Odyssey® Fc system.

Techniques: In Vivo, Staining, Expressing

Journal: Materials Today Bio

Article Title: Copper-based nanozymes synergistically enhance Cuproptosis for psoriasis treatment

doi: 10.1016/j.mtbio.2026.102855

Figure Lengend Snippet: Studies on cuproptosis mediated by Cu-NZs in vitro. (a) Schematic illustration of the cuproptosis pathway. (b–d) Relative mRNA expression levels of cuproptosis-related genes (DLAT, FDX1, LIAS) in HaCaT cells treated with Cu-NZs (7.5 and 15 μg/mL) for 24 h. (e–g) Western blot analysis of cuproptosis-related proteins (DLAT, FDX1, LIAS) in HaCaT cells treated with Cu-NZs (7.5 and 15 μg/mL) for 24 h. (h,i) Confocal microscopy images showing expression and subcellular localization changes of cuproptosis-related proteins (DLAT, LIAS and FDX1) in HaCaT cells treated with Cu-NZs (7.5 and 15 μg/mL) for 24 h (representative images shown). All data are presented as mean ± SD (n = 3). Statistical comparisons were performed using one-way ANOVA followed by Tukey's post hoc test. Significance levels are indicated as follows: ∗∗p < 0.01, ∗∗∗p < 0.001, and ∗∗∗∗p < 0.0001.

Article Snippet: Primary antibodies against DLAT (Proteintech, #13426-1-AP) and FDX1 (Proteintech, #12592-1-AP) were diluted (1:200) in antibody diluent (ZSGB-BIO, #ZLI-9029) and applied overnight at 4 °C.

Techniques: In Vitro, Expressing, Western Blot, Confocal Microscopy

Journal: Materials Today Bio

Article Title: Copper-based nanozymes synergistically enhance Cuproptosis for psoriasis treatment

doi: 10.1016/j.mtbio.2026.102855

Figure Lengend Snippet: In vivo alleviation of psoriatic-like lesions by Cu-NZs in C57 mice. (a) Experimental schedule of the therapeutic regimen in IMQ-induced psoriatic mouse models. (b–e) Psoriasis Area and Severity Index (PASI) scores assessing erythema, scaling, and skin thickness. (f) Macroscopic skin appearance and corresponding H&E-stained skin sections. (g) Epidermal thickness measurements from H&E-stained sections. (h–j) mRNA expression levels of inflammatory cytokines in skin tissues. (k) Expression of cuproptosis-related proteins (DLAT, LIAS, FDX1) in mouse skin as detected by IHC. (l–o) Liver and kidney function markers: alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum creatinine (SCr), and blood urea nitrogen (BUN). All data are presented as mean ± SD (n = 5 per group). For comparisons between two groups, an unpaired t -test was used. For comparisons involving three or more groups, one-way ANOVA followed by Tukey's post hoc test was performed. Significance levels are indicated as follows: ns, not significant; ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001.

Article Snippet: Primary antibodies against DLAT (Proteintech, #13426-1-AP) and FDX1 (Proteintech, #12592-1-AP) were diluted (1:200) in antibody diluent (ZSGB-BIO, #ZLI-9029) and applied overnight at 4 °C.

Techniques: In Vivo, Staining, Expressing

Journal: Materials Today Bio

Article Title: A precise theranostic nanoplatform amplifies anti-tumor efficacy via copper ionophores and sonodynamic therapy

doi: 10.1016/j.mtbio.2026.102957

Figure Lengend Snippet: The anti-tumor immune mechanism of ICCP NPs. a) Schematic illustration of cuproptosis mechanism. b) Immunofluorescence analysis of DLAT and FDX1 in 4T1 cells following various treatments. c) Schematic diagram illustrating the synergistic induction of ICD by SDT and cuproptosis. d) Immunofluorescence analysis of CRT and HMGB1 in 4T1 cells following various treatments. e) Quantitative analysis of CRT fluorescence intensity. f) ATP content in 4T1 cells following various treatments.

Article Snippet: Cells were then incubated overnight at 4 °C with primary rabbit polyclonal antibodies against DLAT (13426-1-AP, 1:200), FDX1 (12592-1-AP, 1:250), CRT (10292-1-AP, 1:200), and HMGB1 (10829-1-AP, 1:200) (Proteintech, Wuhan, China).

Techniques: Immunofluorescence, Fluorescence

Journal: Materials Today Bio

Article Title: A precise theranostic nanoplatform amplifies anti-tumor efficacy via copper ionophores and sonodynamic therapy

doi: 10.1016/j.mtbio.2026.102957

Figure Lengend Snippet: The anti-tumor effect of ICCP NPs in vivo . a) Biodistribution of free IR808 and ICCP NPs in tumor-bearing mice. b) NIR imaging of harvested organs 48 h post-injection. c) Schematic diagram of the anti-tumor experiment in BALB/c mice. d) Body weight fluctuations in tumor-bearing mice following various treatments throughout the therapeutic period. e) Tumor volume growth curves in tumor-bearing mice from different treatments. f) Tumor histological assessment by H&E staining, TUNEL, Ki67 staining, and DLAT immunofluorescence following various treatments.

Article Snippet: Cells were then incubated overnight at 4 °C with primary rabbit polyclonal antibodies against DLAT (13426-1-AP, 1:200), FDX1 (12592-1-AP, 1:250), CRT (10292-1-AP, 1:200), and HMGB1 (10829-1-AP, 1:200) (Proteintech, Wuhan, China).

Techniques: In Vivo, Imaging, Injection, Staining, TUNEL Assay, Immunofluorescence